New hope for diabetic eye disease: higher dose drug shows promise in trial
NCT ID NCT07118670
First seen Mar 28, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests a stronger dose (8mg) of aflibercept in 40 adults with proliferative diabetic retinopathy (PDR) who do not have swelling in the center of the retina. The goal is to see if it can safely improve the severity of the disease and maintain vision over 96 weeks. Participants receive the drug as an injection into the eye.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLIFERATIVE DIABETIC RETINOPATHY (PDR) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Retina Consultants of Texas - Austin Retina Associates
Austin, Texas, 78705, United States
-
Retina Consultants of Texas - San Antonio
San Antonio, Texas, 78240, United States
Conditions
Explore the condition pages connected to this study.